Questcor
Pharmaceuticals Inc (NASDAQ:QCOR) soared 15.23% to $57.88. The Company’s
preliminary June estimates for its shipped paid Acthar prescriptions show
month-to-month increases as the company has worked to broaden physician
awareness for its prescriptions though expansion of its sales force. The
Company reported paid prescriptions treating Nephrotic Syndrome came in at 115 to
120 for June. Questcor Pharmaceuticals has completed the expansion of its
nephrology sales force, increasing its representatives to 58 from 28. Total
Acthar shipments reached 4710 vials for the second quarter ended in June.
The
Company repurchased 3.7 million shares of its common stock during the second
quarter, at an average price of $41.85.
Nanosphere
Inc (NASDAQ:NSPH) among the gainers and the stock escalated 8.15% to $3.45.
Roth Capital upgraded the rating on the stock from neutral to buy.
Recently,
the U.S. Food and Drug Administration have granted a de novo petition
permitting marketing of its Gram-Positive Blood Culture Nucleic Acid Test on
the automated sample-to-result Verigene System.
AMERIGROUP
Corporation (NYSE:AGP) is one of the top percentage gainers and soared 38.0% to
$88.79. WellPoint Inc and AMERIGROUP Corporation have entered into a definitive
agreement. WellPoint will acquire Amerigroup for $92.00 per share in cash by
purchasing all the outstanding shares of Amerigroup. The transaction value is
approximately $4.9 billion. After the acquisition, WellPoint with its
affiliated Medicaid plans will serve more than four-and-a-half million
beneficiaries of state sponsored health care programs.
Ampio
Pharmaceuticals Inc (NASDAQ:AMPE) moved up 2.50% to $4.94. The Company
announced the significant results from their further analysis of its Optina
trial on DME. The primary endpoint was change from baseline to week twelve of
treatment in retinal thickness as measured by Optical Coherence Tomography.
Celgene
Corporation (NASDAQ:CELG) is up marginally 0.23%to $64.89. According to a
source in contact with Celgene management, the Company is not buying Human
Genome Sciences.
No comments:
Post a Comment